revenue from Testosterone was only $263 thousand. I mentioned on...

revenue from Testosterone was only $263 thousand. I mentioned on another thread that Dash was taken over by Natco Pharma US, completed Jan this year ( Natco never replied to my queries) I voiced an opinion that I hope the takeover activity has not taken Dash's focus away from the main game. Looks like that's exactly what has happened. No matter how you look at this its very disappointing. The next thing was does Natco already have a Testosterone product of it own? A quick check seems to say NO. For Natco, Dash and ACR there would be tax incentives to load as many loses onto past financial year. I would like ACR management to explain what went wrong. Returns on invested capital are supposed to be double digit % as each generic costs some 3-4 million to get to market. Dash adding our Testosterone Generic to their product list would have made it look just that much better to Natco..... but once again we in AU have missed out. If our partners are not going broke, they are being taken over. As for the Pagadis partnership, looks like they will take over the Elma Cream Generic from bankrupted Harris.